Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 2
2012 1
2014 1
2019 3
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, Grossi F, De Pas T, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsypin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H. Gregorc V, et al. Among authors: tsypin m. Lancet Oncol. 2014 Jun;15(7):713-21. doi: 10.1016/S1470-2045(14)70162-7. Epub 2014 May 13. Lancet Oncol. 2014. PMID: 24831979 Free article. Clinical Trial.
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Chung CH, et al. Among authors: tsypin m. Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-65. doi: 10.1158/1055-9965.EPI-09-0937. Epub 2010 Jan 19. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20086114 Free PMC article.
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. Carbone DP, et al. Among authors: tsypin m. Lung Cancer. 2010 Sep;69(3):337-40. doi: 10.1016/j.lungcan.2009.11.019. Epub 2009 Dec 29. Lung Cancer. 2010. PMID: 20036440 Free PMC article. Clinical Trial.
Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.
Lazzari C, Spreafico A, Bachi A, Roder H, Floriani I, Garavaglia D, Cattaneo A, Grigorieva J, Viganò MG, Sorlini C, Ghio D, Tsypin M, Bulotta A, Bergamaschi L, Gregorc V. Lazzari C, et al. Among authors: tsypin m. J Thorac Oncol. 2012 Jan;7(1):40-8. doi: 10.1097/JTO.0b013e3182307f17. J Thorac Oncol. 2012. PMID: 21964534 Free article.
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP. Taguchi F, et al. Among authors: tsypin m. J Natl Cancer Inst. 2007 Jun 6;99(11):838-46. doi: 10.1093/jnci/djk195. J Natl Cancer Inst. 2007. PMID: 17551144